Home » Headlines » Currently Reading:

Morning Headlines 8/31/17

August 30, 2017 Headlines 2 Comments

AHA Letter To Representative Pat Tiberi

AHA writes a letter to Rep. Pat Tiberi (R-OH), Chairman of the Committee on Ways and Means’ Subcommittee on Health, calling for the cancellation of Meaningful Use Stage 3.

FDA approval brings first gene therapy to the United States

The FDA has approved CAR-T, a gene therapy treatment for certain types of pediatric leukemia, making it the first gene therapy approved for use in the US. Novartis developed the treatment and has put a $475,000 price tag on the drug, far below analyst expectations. In a clinical trial, a single dose of CAR-T left 83 percent of participants cancer free after three months.

Medtronic invests $40 million in robotics company Mazor

Medtronic announces that it has invested $40 million in surgical robot vendor Mazor Robotics, bringing its total investment in the company to $72 million. Medtronic will now become the exclusive distributor of Mazor’s robotic surgery system.

Aetna scoops up rising star from Wal-Mart’s health group to lead Apple Watch partnership

Aetna hires Walmart’s health division director Ben Wanamaker to lead its joint venture with Apple.

View/Print Text Only View/Print Text Only


HIStalk Featured Sponsors

     

Currently there are "2 comments" on this Article:

  1. Folks should remember that killing MU3 would hurt Medicaid providers much more than hospitals or Medicare EPs. The Medicaid program has a few more years of funding left in it. The other programs – for most hospitals and EPs – do not, and have shifted into the penalty phase.







Subscribe to Updates

Search


Loading

Text Ads


Report News and Rumors

No title

Anonymous online form
E-mail
Rumor line: 801.HIT.NEWS

Tweets

Archives

Founding Sponsors


 

Platinum Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reader Comments

  • Woodstock Generation: Gotta love those O'Jays, hot pink suits et al. In other words, gotta love doo-wop, soul, and all those related sounds t...
  • Vaporware?: JTR, Cerner is re-tooling itself from a software company (sic) into a service company. The company needs a place to put ...
  • Dave Butler: Many similar issues that I've found as well during my time with provider groups. The EHRs screen can be really busy and ...
  • Justa Trench Rat: Nice to see Cerner continuing with their new campus. I am sure our implementation of their highly questionable revenue ...
  • FRANK POGGIO: Shows to go ya...answering black and white Jeopardy questions is a far cry from the massive grey area of medicine/pharma...
  • Number Cruncher: You are right AC. The cost is seriously underestimated here. Just looking at the numbers - $1 B for 5 years = $200 M ...
  • Abraham Van Helsing: Re Theranos. Will be interesting to follow the saga. As I and others had noted going back 2+ years, something was obvi...
  • Prof. Moriarty: Re: Watson pull out. I've not been directly involved with this product, but from its beginning I have always seen Watso...
  • mih: Of course they can, and for much much cheaper. But why would they do it? Existing arrangement works for everyone in the ...
  • Andrew M. Harrison: Thanks for (actually) reading our paper. I enjoyed the story of your friend, as well as the translation of numbers to em...

RSS Industry Events

  • An error has occurred, which probably means the feed is down. Try again later.

Sponsor Quick Links